Page 79 - Read Online
P. 79

Page 8 of 8          Bellu et al. J Cancer Metastasis Treat 2021;7:29  https://dx.doi.org/10.20517/2394-4722.2021.89

               Ethical approval and consent to participate
               The study was approved by the Veneto Institute of Oncology Ethics Commitee.


               Consent for publication
               All the patients signed the informed consent form.


               Copyright
               ©The Author(s) 2021.


               REFERENCES
               1.       Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous
                   System: a summary. Acta Neuropathol (Berl) 2016;131:803-20.  DOI  PubMed
               2.       Taillibert S, Chodkiewicz C, Laigle-Donadey F, Napolitano M, Cartalat-Carel S, Sanson M. Gliomatosis cerebri: a review of 296 cases
                   from the ANOCEF Database and the Literature. J Neurooncol 2006;76:201-5.  DOI  PubMed
               3.       van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of
                   outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011;12:583-93.  DOI  PubMed
               4.       Carroll KT, Hirshman B, Ali MA, et al. Management and survival patterns of patients with gliomatosis cerebri: a SEER-based
                   analysis. World Neurosurg 2017;103:186-93.  DOI  PubMed
               5.       Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in
                   neuro-oncology working group. J Clin Oncol 2010;28:1963-72.  DOI  PubMed
               6.       Desestret V, Ciccarino P, Ducray F, et al. Prognostic stratification of gliomatosis cerebri by IDH1R132H and INA expression. J
                   Neurooncol 2011;105:219-24.  DOI  PubMed
               7.       Greenfield JP, Castañeda Heredia A, George E, Kieran MW, Morales La Madrid A. Gliomatosis cerebri: a consensus summary report
                   from the First International Gliomatosis cerebri Group Meeting, March 26-27, 2015, Paris, France.  Pediatr Blood Cancer
                   2016;63:2072-7.  DOI  PubMed
               8.       Chen S, Tanaka S, Giannini C, et al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol
                   2013;112:267-75.  DOI  PubMed  PMC
               9.       Glas M, Bähr O, Felsberg J, et al. NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol
                   2011;70:445-53.  DOI  PubMed
               10.      Rudà R, Bertero L, Sanson M. Gliomatosis cerebri: a review. Curr Treat Options Neurol 2014;16:273.  DOI  PubMed
               11.      Sanson M, Napolitano M, Cartalat-Carel S, Taillibert S. La gliomatose cérébrale. Rev Neurol (Paris) 2005;161:173-81.  DOI  PubMed
               12.      Sanson M, Cartalat-Carel S, Taillibert S, et al. Initial chemotherapy in gliomatosis cerebri. Neurology 2004;63:270.  DOI  PubMed
               13.      Kong DS, Kim ST, Lee JI, et al. Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC Cancer 2010;10:424.  DOI  PubMed
                   PMC
               14.      Shimony N, Shofty B, Ram Z, Grossman R. Perioperative risk assessment of patients with gliomatosis cerebri. World Neurosurg
                   2017;98:334-8.  DOI  PubMed
               15.      Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and
                   grading of brain tumors: systematic review and meta-analysis. Neuro Oncol 2015;18:426-34.  DOI  PubMed  PMC
               16.      Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosis cerebri to temozolomide and whole brain radiotherapy. Clin
                   Neurol Neurosurg 2012;114:299-306.  DOI  PubMed
               17.      Baumert BG, Hegi ME, van den Bent MJ, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma
                   (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 2016;17:1521-32.  DOI  PubMed  PMC
               18.      Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with
                   procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27:5874-80.  DOI  PubMed
               19.      Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med
                   2016;374:1344-55.  DOI  PubMed  PMC
               20.      Bell EH, Zhang P, Shaw EG, et al. Comprehensive genomic analysis in NRG oncology/RTOG 9802: a phase III trial of radiation
                   versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol 2020;38:3407-17.
                   DOI  PubMed  PMC
   74   75   76   77   78   79   80   81   82   83   84